Telomere Therapeutics

Telomere Therapeutics is a gene therapy company developing disease modifying treatments for unmet medical needs, pioneering the repair of telomeres to treat organ fibrosis and other telomere-dysfunction syndromes for which there are no curative treatments. Their lead program is an AAV-based therapy primarily focused on idiopathic pulmonary fibrosis (IPF), a disease with very poor prognosis and a high mortality rate, estimated at <5 years after diagnosis.